Enterome | Evaluate

December 02, 2022

Burned by Palforzia, Nestlé retreats from its pharma experiment

The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?

October 06, 2022

SITC 2022 preview – cytokines and oral checkpoints

Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.

January 05, 2021

Hope versus experience in glioblastoma

Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.

October 23, 2018

Takeda goes with its gut again as it strikes $50m deal with Enterome

February 22, 2017

Asco-SITC – Oncology could give gutsy biotechs another chance

August 01, 2016

Seres failure a kick in the gut to microbiome field

April 22, 2016

Upcoming events – Cara, Heron and Seres get ready for next phase

January 28, 2016

Interview – Enterome has a good gut feeling about 2016

May 22, 2014

Interview – Galmed’s early move to open up liver market